Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Karacorlu M, Ozdemir H, Karacorlu S, Alacali N, Mudun B, Burumcek E . Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. Eye 2005; 19(4): 382–386.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–713.
The Diabetes Control and Complications Trial Research Group (DCCT). Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 1996; 276: 1409–1415.
Miyake K, Ota I, Ibaraki N, Akura J, Ichibashi S, Shibuya Y . Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia. Arch Ophthalmol. 2001; 119: 387–394.
Harris A, Jonescu-Cuypers CP . The impact of glaucoma medication on parameters of ocular perfusion. Curr Opin Ophthalmol 2001; 12: 131–137.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ziahosseini, K., Fong, K. & Horgan, S. Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. Eye 20, 861–862 (2006). https://doi.org/10.1038/sj.eye.6702037
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6702037
